Vanda Pharmaceuticals
VNDA
136 hedge funds and large institutions have $556M invested in Vanda Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 53 reducing their positions, and 19 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
15% more call options, than puts
Call options by funds: $721K | Put options by funds: $625K
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
2.13% less ownership
Funds ownership: 92.47% → 90.34% (-2.1%)
4% less funds holding
Funds holding: 141 → 136 (-5)
13% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 53
14% less capital invested
Capital invested by funds: $648M → $556M (-$92.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$54.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$33.3M |
| 3 |
AC
Armistice Capital
New York
|
+$14.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.62M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$16M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$11.7M |
| 3 |
CM
Castleark Management
Chicago,
Illinois
|
-$9.31M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$7.95M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$7.48M |
VNDA Hedge Fund Activity: Q1 2017 in Review
136 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2017, worth a combined $556M — down 14% from $648M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new VNDA positions and 19 closed out — a net gain of 2 holders — while 46 added to existing stakes and 53 trimmed.
The largest buyer was BlackRock, adding an estimated $54.8M. The largest seller was Deerfield Management, cutting an estimated $16M.
- 136 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2017, down from 141 in Q4 2016.
- Funds reported $556M of Vanda Pharmaceuticals stock for Q1 2017, down 14% quarter-over-quarter.
- 21 funds opened new Vanda Pharmaceuticals positions in Q1 2017 and 19 closed out, a net change of +2 holders.
- The largest Vanda Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $54.8M added.
- The largest Vanda Pharmaceuticals seller in Q1 2017 was Deerfield Management, an estimated $16M sold.
Based on aggregated 13F filings for Q1 2017.